$Abivax S.A. (ABVX.US)$ Abivax Provides Update on Ulcerative...

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Abivax has announced initial preclinical combination data of obefazimod and etrasimod in an inflammatory bowel disease (IBD) mouse model. The company is conducting studies with multiple oral and injectable therapies, with additional data expected in Q4 2024. The preclinical evaluation showed improved body weight protection and Disease Activity Index, with a synergistic and statistically significant reduction of several cytokines compared to individual treatments.

Abivax aims to develop a fixed-dose combination therapy for ulcerative colitis (UC) patients, targeting best-in-disease state induction and maintenance efficacy. The company believes obefazimod's safety and efficacy profile makes it an attractive candidate for combination with other mechanisms of action. Abivax plans to select a candidate in 2025 and develop a fixed-dose combination for clinical development.